Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Ascending Doses of IRL201104 in Healthy Volunteers
NCT04748536Phase 1Completed
- Sponsor
- Revolo Biotherapeutics
- Start
- Jan 2021
- Primary completion
- Apr 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IRL201104 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Revolo Biotherapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 35 days, Potentially Clinically Important Abnormal Haematology Variables at 21 days and 3 more. Started Jan 2021; status: completed.
02
Drugs
IRL201104
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04748536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04748536.